Tetra Bio-Pharma Inc. announces today that it has granted, pursuant to the Company's stock option plan (the "Plan"), 375,000 options to officers of the Company. Each option entitles its holder to purchase one common share of the Company.
Crescita Therapeutics Inc. and Tetra Natural Health today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™.
Tetra Bio-Pharma Inc. today announced it has entered into a definitive agreement with the shareholders (the "Vendors") of Panag Pharma Inc. for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag.
Tetra Bio-Pharma Inc. has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.
Tetra Bio-Pharma Inc. today announced that its Phase 1 clinical trial in healthy volunteers using vaporized PPP001 has been successfully concluded. This trial was aimed at determining the pharmacokinetics (PK) and safety of a 4-day titration followed by a single dose of vaporized PPP001 in 12 healthy volunteers.
Tetra Bio-Pharma Inc. confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects.
Tetra Bio-Pharma Inc. has announced that it is in process of filing a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that allows for patent protection.
Recent news regarding Aphria Inc. does not in any way affect Tetra’s business, operations, clinical and drug registration and source of supply. We are well funded to continue these activities in 2019 with plans to expand our clinical activities in the U.S.
Tetra Bio-Pharma Inc. has closed a private placement of units with its strategic partner Aphria Inc.
Tetra Bio-Pharma Inc. and Altus Formulation Inc. today announced the signing of a non-binding term sheet to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications.